Shape Therapeutics’ SHP-201, an experimental gene therapy for Parkinson’s disease, significantly reduced the levels of alpha-synuclein — a protein that plays a key role in the development of the neurodegenerative […] The post Parkinson’s gene therapy reduced alpha-synuclein in animal models appeared first on Parkinson's News Today.
